ID   COLO 320DM
AC   CVCL_0219
SY   COLO-320DM; COLO_320DM; COLO-320-DM; COLO #320DM; COLO320/DM; COLO320-DM; COLO320DM; Colo320DM; COLO320 DM; COLO 320 DM; COLO 320 (DM); Colorado 320 Double Minutes
DR   CLO; CLO_0002546
DR   EFO; EFO_0002136
DR   MCCL; MCC:0000108
DR   CLDB; cl827
DR   ArrayExpress; E-MTAB-2706
DR   ATCC; CCL-220
DR   BCRC; 60108
DR   BioSample; SAMN03471612
DR   cancercelllines; CVCL_0219
DR   CCRID; 1101HUM-PUMC000133
DR   CCRID; 3101HUMTCHu208
DR   CCTCC; GDC0042
DR   ChEMBL-Cells; CHEMBL3307647
DR   ChEMBL-Targets; CHEMBL614562
DR   CLS; 300153
DR   ColonAtlas; COLO320DM
DR   Cosmic; 808509
DR   Cosmic; 1043807
DR   Cosmic; 1223136
DR   Cosmic; 1310932
DR   Cosmic; 1312298
DR   Cosmic; 1374635
DR   Cosmic; 1466812
DR   Cosmic; 2301969
DR   Cosmic; 2668253
DR   Cosmic; 2664052
DR   Cosmic; 2760069
DR   Cosmic; 2811047
DR   ECACC; 87061205
DR   EGA; EGAS00001000610
DR   GEO; GSM206461
DR   GEO; GSM274777
DR   GEO; GSM513909
DR   GEO; GSM514187
DR   GEO; GSM739989
DR   GEO; GSM739990
DR   GEO; GSM739991
DR   GEO; GSM740012
DR   GEO; GSM784007
DR   GEO; GSM827245
DR   GEO; GSM1346834
DR   GEO; GSM1374454
DR   GEO; GSM1374455
DR   GEO; GSM1448173
DR   IARC_TP53; 4553
DR   JCRB; JCRB0225
DR   KCB; KCB 200694YJ
DR   KCLB; 10220
DR   LINCS_LDP; LCL-1197
DR   PharmacoDB; COLO320DM_216_2019
DR   PRIDE; PXD005354
DR   PRIDE; PXD005355
DR   Progenetix; CVCL_0219
DR   PubChem_Cell_line; CVCL_0219
DR   SKY/M-FISH/CGH; 5014
DR   TOKU-E; 985
DR   Wikidata; Q54814089
RX   PubMed=498117;
RX   PubMed=3164477;
RX   PubMed=7651727;
RX   PubMed=7874267;
RX   PubMed=9290701;
RX   PubMed=16418264;
RX   PubMed=18258742;
RX   PubMed=19927377;
RX   PubMed=20215515;
RX   PubMed=20606684;
RX   PubMed=22538498;
RX   PubMed=23272949;
RX   PubMed=24755471;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25926053;
RX   PubMed=26589293;
RX   PubMed=28179481;
RX   PubMed=28196595;
RX   PubMed=29101300;
WW   https://tcpaportal.org/mclp/
CC   Part of: AstraZeneca Colorectal cell line (AZCL) panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   HLA typing: A*24:02,24:02; B*14:02,39:10; C*08:02,08:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (PubMed=24755471; PubMed=25926053).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser811Ter (c.2432C>G); ClinVar=VCV002203685; Zygosity=Unspecified (PubMed=24755471; PubMed=28179481).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=7651727; PubMed=16418264; PubMed=24755471).
CC   Omics: Deep proteome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Misspelling: COLD-320-DM; Cosmic=1466812.
CC   Derived from site: In situ; Colon, sigmoid; UBERON=UBERON_0001159.
ST   Source(s): ATCC; CCRID; CLS; ECACC; JCRB; KCLB; PubMed=25877200; PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 11 (ATCC; CCRID; CLS; JCRB; KCLB; PubMed=25877200; PubMed=25926053)
ST   CSF1PO: 11,12 (ECACC)
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 15
ST   D19S433: 16.2
ST   D21S11: 31,33.2 (PubMed=25926053)
ST   D21S11: 33.2 (CCRID; CLS; PubMed=25877200)
ST   D2S1338: 18,25
ST   D3S1358: 17
ST   D5S818: 12
ST   D7S820: 9,12
ST   D8S1179: 13
ST   FGA: 20
ST   Penta D: 9,12
ST   Penta E: 11
ST   TH01: 8,9 (ECACC)
ST   TH01: 9 (ATCC; CCRID; CLS; JCRB; KCLB; PubMed=25877200; PubMed=25926053)
ST   TPOX: 8,9
ST   vWA: 15,18
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1989 ! COLO 320
SX   Female
AG   55Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 37
//
RX   PubMed=498117;
RA   Quinn L.A., Moore G.E., Morgan R.T., Woods L.K.;
RT   "Cell lines from human colon carcinoma with unusual cell products,
RT   double minutes, and homogeneously staining regions.";
RL   Cancer Res. 39:4914-4924(1979).
//
RX   PubMed=3164477; DOI=10.1073/pnas.85.13.4804;
RA   Von Hoff D.D., Needham-VanDevanter D.R., Yucel J., Windle B.E.,
RA   Wahl G.M.;
RT   "Amplified human MYC oncogenes localized to replicating submicroscopic
RT   circular DNA molecules.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:4804-4808(1988).
//
RX   PubMed=7651727;
RA   Kastrinakis W.V., Ramchurren N., Rieger K.M., Hess D.T., Loda M.,
RA   Steele G., Summerhayes I.C.;
RT   "Increased incidence of p53 mutations is associated with hepatic
RT   metastasis in colorectal neoplastic progression.";
RL   Oncogene 11:647-652(1995).
//
RX   PubMed=7874267; DOI=10.1007/BF02349278;
RA   Ikuta S., Itoh F., Hinoda Y., Toyota M., Makiguchi Y., Imai K.,
RA   Yachi A.;
RT   "Expression of cytoskeletal-associated protein tyrosine phosphatase
RT   PTPH1 mRNA in human hepatocellular carcinoma.";
RL   J. Gastroenterol. 29:727-732(1994).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=16418264; DOI=10.1073/pnas.0510146103;
RA   Liu Y., Bodmer W.F.;
RT   "Analysis of P53 mutations and their expression in 56 colorectal
RT   cancer cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).
//
RX   PubMed=18258742; DOI=10.1073/pnas.0712176105;
RA   Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.;
RT   "Cell growth, global phosphotyrosine elevation, and c-Met
RT   phosphorylation through Src family kinases in colorectal cancer
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).
//
RX   PubMed=19927377; DOI=10.1002/gcc.20730;
RA   Knutsen T., Padilla-Nash H.M., Wangsa D., Barenboim-Stapleton L.,
RA   Camps J., McNeil N.E., Difilippantonio M.J., Ried T.;
RT   "Definitive molecular cytogenetic characterization of 15 colorectal
RT   cancer cell lines.";
RL   Genes Chromosomes Cancer 49:204-223(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20606684; DOI=10.1038/sj.bjc.6605780;
RA   Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.;
RT   "5-fluorouracil response in a large panel of colorectal cancer cell
RT   lines is associated with mismatch repair deficiency.";
RL   Br. J. Cancer 103:340-346(2010).
//
RX   PubMed=22538498; DOI=10.1159/000338793;
RA   Grozinsky-Glasberg S., Shimon I., Rubinfeld H.;
RT   "The role of cell lines in the study of neuroendocrine tumors.";
RL   Neuroendocrinology 96:173-187(2012).
//
RX   PubMed=23272949; DOI=10.1186/1755-8794-5-66;
RA   Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A.,
RA   Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A.,
RA   Orphanides G., French T., Wessels L.F.A.;
RT   "Subtypes of primary colorectal tumors correlate with response to
RT   targeted treatment in colorectal cell lines.";
RL   BMC Med. Genomics 5:66.1-66.15(2012).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=28179481; DOI=10.1158/1535-7163.MCT-16-0578;
RA   Tanaka N., Mashima T., Mizutani A., Sato A., Aoyama A., Gong B.,
RA   Yoshida H., Muramatsu Y., Nakata K., Matsuura M., Katayama R.,
RA   Nagayama S., Fujita N., Sugimoto Y., Seimiya H.;
RT   "APC mutations as a potential biomarker for sensitivity to tankyrase
RT   inhibitors in colorectal cancer.";
RL   Mol. Cancer Ther. 16:752-762(2017).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29101300; DOI=10.15252/msb.20177701;
RA   Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R.-S.,
RA   Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S.,
RA   Johnstone E., Domingo E., Kerr D., Jesinghaus M., Slotta-Huspenina J.,
RA   Weichert W., Knapp S., Feller S.M., Kuster B.;
RT   "Pharmacoproteomic characterisation of human colon and rectal
RT   cancer.";
RL   Mol. Syst. Biol. 13:951-951(2017).
//